These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 16690359)
1. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Small EJ; Carducci MA; Burke JM; Rodriguez R; Fong L; van Ummersen L; Yu DC; Aimi J; Ando D; Working P; Kirn D; Wilding G Mol Ther; 2006 Jul; 14(1):107-17. PubMed ID: 16690359 [TBL] [Abstract][Full Text] [Related]
2. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. DeWeese TL; van der Poel H; Li S; Mikhak B; Drew R; Goemann M; Hamper U; DeJong R; Detorie N; Rodriguez R; Haulk T; DeMarzo AM; Piantadosi S; Yu DC; Chen Y; Henderson DR; Carducci MA; Nelson WG; Simons JW Cancer Res; 2001 Oct; 61(20):7464-72. PubMed ID: 11606381 [TBL] [Abstract][Full Text] [Related]
3. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Dilley J; Reddy S; Ko D; Nguyen N; Rojas G; Working P; Yu DC Cancer Gene Ther; 2005 Aug; 12(8):715-22. PubMed ID: 15832172 [TBL] [Abstract][Full Text] [Related]
4. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Freytag SO; Khil M; Stricker H; Peabody J; Menon M; DePeralta-Venturina M; Nafziger D; Pegg J; Paielli D; Brown S; Barton K; Lu M; Aguilar-Cordova E; Kim JH Cancer Res; 2002 Sep; 62(17):4968-76. PubMed ID: 12208748 [TBL] [Abstract][Full Text] [Related]
5. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Nemunaitis J; Cunningham C; Buchanan A; Blackburn A; Edelman G; Maples P; Netto G; Tong A; Randlev B; Olson S; Kirn D Gene Ther; 2001 May; 8(10):746-59. PubMed ID: 11420638 [TBL] [Abstract][Full Text] [Related]
6. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Trudel S; Trachtenberg J; Toi A; Sweet J; Li ZH; Jewett M; Tshilias J; Zhuang LH; Hitt M; Wan Y; Gauldie J; Graham FL; Dancey J; Stewart AK Cancer Gene Ther; 2003 Oct; 10(10):755-63. PubMed ID: 14502228 [TBL] [Abstract][Full Text] [Related]
7. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer. van der Linden RR; Haagmans BL; Mongiat-Artus P; van Doornum GJ; Kraaij R; Kadmon D; Aguilar-Cordova E; Osterhaus AD; van der Kwast TH; Bangma CH Eur Urol; 2005 Jul; 48(1):153-61. PubMed ID: 15967266 [TBL] [Abstract][Full Text] [Related]
8. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509 [TBL] [Abstract][Full Text] [Related]
9. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062 [TBL] [Abstract][Full Text] [Related]
10. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Reid T; Galanis E; Abbruzzese J; Sze D; Wein LM; Andrews J; Randlev B; Heise C; Uprichard M; Hatfield M; Rome L; Rubin J; Kirn D Cancer Res; 2002 Nov; 62(21):6070-9. PubMed ID: 12414631 [TBL] [Abstract][Full Text] [Related]
11. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial. Atencio IA; Grace M; Bordens R; Fritz M; Horowitz JA; Hutchins B; Indelicato S; Jacobs S; Kolz K; Maneval D; Musco ML; Shinoda J; Venook A; Wen S; Warren R Cancer Gene Ther; 2006 Feb; 13(2):169-81. PubMed ID: 16082381 [TBL] [Abstract][Full Text] [Related]
12. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704 [TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. Rademaker-Lakhai JM; Horenblas S; Meinhardt W; Stokvis E; de Reijke TM; Jimeno JM; Lopez-Lazaro L; Lopez Martin JA; Beijnen JH; Schellens JH Clin Cancer Res; 2005 Mar; 11(5):1854-62. PubMed ID: 15756010 [TBL] [Abstract][Full Text] [Related]
14. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Buller RE; Runnebaum IB; Karlan BY; Horowitz JA; Shahin M; Buekers T; Petrauskas S; Kreienberg R; Slamon D; Pegram M Cancer Gene Ther; 2002 Jul; 9(7):553-66. PubMed ID: 12082455 [TBL] [Abstract][Full Text] [Related]
15. Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors. Xu F; Li S; Li XL; Guo Y; Zou BY; Xu R; Liao H; Zhao HY; Zhang Y; Guan ZZ; Zhang L Cancer Gene Ther; 2009 Sep; 16(9):723-30. PubMed ID: 19363470 [TBL] [Abstract][Full Text] [Related]
16. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Eder JP; Kantoff PW; Roper K; Xu GX; Bubley GJ; Boyden J; Gritz L; Mazzara G; Oh WK; Arlen P; Tsang KY; Panicali D; Schlom J; Kufe DW Clin Cancer Res; 2000 May; 6(5):1632-8. PubMed ID: 10815880 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Burch PA; Croghan GA; Gastineau DA; Jones LA; Kaur JS; Kylstra JW; Richardson RL; Valone FH; Vuk-Pavlović S Prostate; 2004 Aug; 60(3):197-204. PubMed ID: 15176049 [TBL] [Abstract][Full Text] [Related]
18. Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. Liu G; Oettel K; Ripple G; Staab MJ; Horvath D; Alberti D; Arzoomanian R; Marnocha R; Bruskewitz R; Mazess R; Bishop C; Bhattacharya A; Bailey H; Wilding G Clin Cancer Res; 2002 Sep; 8(9):2820-7. PubMed ID: 12231522 [TBL] [Abstract][Full Text] [Related]
19. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Li JL; Liu HL; Zhang XR; Xu JP; Hu WK; Liang M; Chen SY; Hu F; Chu DT Gene Ther; 2009 Mar; 16(3):376-82. PubMed ID: 19092859 [TBL] [Abstract][Full Text] [Related]
20. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial. Brill TH; Kübler HR; von Randenborgh H; Fend F; Pohla H; Breul J; Hartung R; Paul R; Schendel DJ; Gansbacher B J Gene Med; 2007 Jul; 9(7):547-60. PubMed ID: 17514769 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]